A Randomized, Open-label, Parallel Group, Multi-center Phase II Clinical Trial DCVAC/OvCa Added to Standard Chemotherapy in Women With Relapsed Platinum Sensitive Epithelial Ovarian Carcinoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 17 May 2017
At a glance
- Drugs DCVAC OvCa (Primary) ; Carboplatin; Gemcitabine
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Sponsors SOTIO
- 10 May 2017 Planned End Date changed from 1 Feb 2017 to 1 Nov 2017.
- 12 Jan 2016 Planned End Date changed from 1 Mar 2017 to 1 Feb 2017, as reported by ClinicalTrials.gov.
- 12 Jan 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Nov 2016, as reported by ClinicalTrials.gov.